Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

White matter abnormalities in dystonia normalize after botulinum toxin treatment.

Blood AJ, Tuch DS, Makris N, Makhlouf ML, Sudarsky LR, Sharma N.

Neuroreport. 2006 Aug 21;17(12):1251-5.

2.

Botulinum toxin modulates basal ganglia but not deficient somatosensory activation in orofacial dystonia.

Dresel C, Bayer F, Castrop F, Rimpau C, Zimmer C, Haslinger B.

Mov Disord. 2011 Jul;26(8):1496-502. doi: 10.1002/mds.23497. Epub 2011 May 20.

PMID:
21604301
3.

Craniocervical dystonia: clinical and pathophysiological features.

Colosimo C, Suppa A, Fabbrini G, Bologna M, Berardelli A.

Eur J Neurol. 2010 Jul;17 Suppl 1:15-21. doi: 10.1111/j.1468-1331.2010.03045.x. Review.

PMID:
20590803
4.

Focal dystonia: the role of botulinum toxin.

Tintner R, Jankovic J.

Curr Neurol Neurosci Rep. 2001 Jul;1(4):337-45. Review.

PMID:
11898539
5.

Task-free functional MRI in cervical dystonia reveals multi-network changes that partially normalize with botulinum toxin.

Delnooz CC, Pasman JW, Beckmann CF, van de Warrenburg BP.

PLoS One. 2013 May 1;8(5):e62877. doi: 10.1371/journal.pone.0062877. Print 2013.

6.

Botulinum toxin treatment of occupational and focal hand dystonia.

Karp BI.

Mov Disord. 2004 Mar;19 Suppl 8:S116-9. Review.

PMID:
15027063
7.

Restoring balance in focal limb dystonia with botulinum toxin.

Sheean G.

Disabil Rehabil. 2007 Dec 15;29(23):1778-88. Review.

PMID:
18033603
8.

[Secondary focal dystonia].

Deligny C, Raoul S, de Ferron E, Auffray E, Guillon B.

Rev Neurol (Paris). 2004 Oct;160(10):983-5. French. No abstract available.

PMID:
15492727
9.

Dystonia in Machado-Joseph disease: Clinical profile, therapy and anatomical basis.

Nunes MB, Martinez AR, Rezende TJ, Friedman JH, Lopes-Cendes I, D'Abreu A, França MC Jr.

Parkinsonism Relat Disord. 2015 Dec;21(12):1441-7. doi: 10.1016/j.parkreldis.2015.10.016. Epub 2015 Oct 30.

PMID:
26552869
10.

Long-term follow-up of botulinum toxin therapy for focal hand dystonia: outcome at 10 years or more.

Lungu C, Karp BI, Alter K, Zolbrod R, Hallett M.

Mov Disord. 2011 Mar;26(4):750-3. doi: 10.1002/mds.23504. Epub 2011 Feb 1.

11.

Severe tongue protrusion dystonia: clinical syndromes and possible treatment.

Schneider SA, Aggarwal A, Bhatt M, Dupont E, Tisch S, Limousin P, Lee P, Quinn N, Bhatia KP.

Neurology. 2006 Sep 26;67(6):940-3.

PMID:
17000958
12.

[Botulinum toxin therapy: from dreaded biological toxin to standard pharmaceutical].

Schnider P, Voller B, Moraru K, Auff E.

Wien Klin Wochenschr. 1999 Oct 29;111(20):825-9. Review. German. No abstract available.

PMID:
10586486
13.

Delayed-onset focal dystonia of the leg secondary to traumatic brain injury.

Kemp S, Kim SD, Cordato DJ, Fung VS.

J Clin Neurosci. 2012 Jun;19(6):916-7. doi: 10.1016/j.jocn.2011.08.025. Epub 2012 Feb 14.

PMID:
22341145
14.

Temporomandibular disorders in patients with craniocervical dystonia.

Costa AL, Campos LS, França Jr MC, D'Abreu A.

Arq Neuropsiquiatr. 2011 Dec;69(6):896-9.

15.

Factors predicting improvement in motor disability in writer's cramp treated with botulinum toxin.

Djebbari R, du Montcel ST, Sangla S, Vidal JS, Gallouedec G, Vidailhet M.

J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1688-91.

16.

Botulinum toxin therapy of writer's cramp.

Das CP, Dressler D, Hallett M.

Eur J Neurol. 2006 Feb;13 Suppl 1:55-9. Review.

PMID:
16417599
17.

Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review.

Colosimo C, Tiple D, Berardelli A.

Neurotox Res. 2012 Nov;22(4):265-73. Epub 2012 Feb 23. Review.

PMID:
22359151
18.

Botulinum toxin therapy for cervical dystonia.

Walker FO.

Phys Med Rehabil Clin N Am. 2003 Nov;14(4):749-66, vi. Review.

PMID:
14580035
19.

Dystonias and botulinum toxin.

Khadilkar SV.

J Assoc Physicians India. 2003 May;51:443-4. No abstract available.

PMID:
12974422
20.

Supplemental Content

Support Center